Australia markets close in 26 minutes
  • ALL ORDS

    6,859.10
    +87.10 (+1.29%)
     
  • ASX 200

    6,649.00
    +87.40 (+1.33%)
     
  • AUD/USD

    0.7313
    +0.0026 (+0.36%)
     
  • OIL

    43.46
    +0.40 (+0.93%)
     
  • GOLD

    1,821.60
    -16.20 (-0.88%)
     
  • BTC-AUD

    25,054.30
    -76.58 (-0.30%)
     
  • CMC Crypto 200

    368.11
    +6.68 (+1.85%)
     
  • AUD/EUR

    0.6171
    +0.0019 (+0.32%)
     
  • AUD/NZD

    1.0493
    -0.0033 (-0.31%)
     
  • NZX 50

    12,553.38
    +51.64 (+0.41%)
     
  • NASDAQ

    11,905.94
    -0.50 (-0.00%)
     
  • FTSE

    6,333.84
    -17.61 (-0.28%)
     
  • Dow Jones

    29,591.27
    +327.79 (+1.12%)
     
  • DAX

    13,126.97
    -10.28 (-0.08%)
     
  • Hang Seng

    26,498.67
    +12.47 (+0.05%)
     
  • NIKKEI 225

    26,225.19
    +697.82 (+2.73%)
     

Aerie Pharmaceuticals to Announce Third Quarter 2020 Financial Results and Host Conference Call on Thursday, November 5, 2020

·3-min read

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, announced today that its third quarter 2020 financial results will be released after the market closes on Thursday, November 5, 2020. Following the release, the Company will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the Company’s financial results and provide a general business update.

The live webcast and a replay may be accessed by visiting the Company’s website at http://investors.aeriepharma.com. Please connect to the Company’s website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. Alternatively, please call (888) 734-0328 (U.S.) or (678) 894-3054 (international) to listen to the live conference call. The conference ID number for the live call is 6776445. Please dial in approximately 10 minutes prior to the call. Telephone replay will be available approximately two hours after the call. To access the replay, please call (855) 859-2056 (U.S.) or (404) 537-3406 (international). The conference ID number for the replay is 6776445. The telephone replay will be available until November 13, 2020.

About Aerie Pharmaceuticals, Inc.

Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie’s first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rhopressa®, including the product label, is available at www.rhopressa.com. Aerie’s second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rocklatan®, including the product label, is available at www.rocklatan.com. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema. More information is available at www.aeriepharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201027005043/en/

Contacts

Media: Tad Heitmann 949-526-8747; theitmann@aeriepharma.com
Investors: Ami Bavishi 908-947-3949; abavishi@aeriepharma.com